IO103

P2a, N=6, Terminated, Lene Meldgaard Knudsen | N=20 --> 6 | Recruiting --> Terminated; Insufficient recruitment within planned enrolmentperiod.

P2, N=19, Completed, Lars Møller Pedersen | Active, not recruiting --> Completed

P2; N=90; Not yet recruiting; Sponsor:IO Biotech

Immune responses against IO103 were induced in blood samples from nine of ten and skin-infiltrating lymphocytes from five of the nine patients. The regressions seen in non-target tumors suggest that IO103 may be effective against a subtype of BCC.

P2, N=20, Active, not recruiting, Lars Møller Pedersen | Trial completion date: Oct 2020 --> Mar 2021 | Trial primary completion date: Oct 2020 --> Mar 2021

This study has prompted the initiation of later phase trials to assess the vaccines efficacy. clinicaltrials.org, identifier NCT03042793.

Background The IDO/PD-L1 (IO102/IO103)1 peptide vaccine is a first-in-class immunomodulatory vaccine containing single IDO- and PD-L1-derived long peptide sequences designed to engage and activate IDO and PD-L1 specific T-cells mediating immune switch. Funding: Has not received any funding. Clinical trial identification: NCT03047928.

P2, N=20, Active, not recruiting, Lars Møller Pedersen | Recruiting --> Active, not recruiting

In this exploratory study, one target tumor achieved partial response. Nonetheless, the two clearances and one partial response of non-target tumors suggest that IO103 may be effective against BCCs. The vaccine was well tolerated.